The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma – a Large, Multicenter Study

Estimating the survival impact of not receiving CAR T therapy while being eligible for treatment

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 38.1-Month Median Follow-up

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Mantle Cell Lymphoma Who Are Naive to Bruton Tyrosine Kinase Inhibitors

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma in the US: A CIBMTR Report

Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in ZUMA-3 Pivotal Study

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Real-World Outcomes for Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia by High-Risk Features and Prior Treatments: Updated Evidence From the CIBMTR Registry

Five-Year Outcomes of Patients With Relapsed or Refractory Mantle Cell Lymphoma Treated With Brexucabtagene Autoleucel in ZUMA-2 Cohorts 1 and 2

Predictors of Early Safety Outcomes With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-cell Malignancies

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results From the iMMagine-1 Trial